戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  Nav1.5 blocking properties of fluoxetine, a selective serotonin reuptake inhibitor.
2 lerance or lack of remission with an initial selective serotonin reuptake inhibitor.
3 lesions; both behaviours are alleviated by a selective serotonin reuptake inhibitor.
4 owing would be unresponsive to fluoxetine, a selective serotonin reuptake inhibitor.
5 serotonin in rat frontal cortex typical of a selective serotonin reuptake inhibitor.
6 al hippocampus following administration of a selective serotonin reuptake inhibitor.
7 CK1) inhibitor, the other from paroxetine, a selective serotonin-reuptake inhibitor.
8 hotics to Depressive patients medicated with Selective Serotonin Reuptake Inhibitors.
9  hypersensitivity, and response to long-term selective serotonin reuptake inhibitors.
10 ve add-on in patients that do not respond to selective serotonin reuptake inhibitors.
11 tment in the absence of prenatal exposure to selective serotonin reuptake inhibitors.
12 more sensitive to SERT inhibitors, including selective serotonin reuptake inhibitors.
13 ic dementia, often respond to treatment with selective serotonin reuptake inhibitors.
14 ries the same FDA "black box" warning as the selective serotonin reuptake inhibitors.
15 ples; and pharmacological treatments, mainly selective serotonin reuptake inhibitors.
16 ffects beyond 12 weeks outside of those with selective serotonin reuptake inhibitors.
17 .90), compared with patients who did not use selective serotonin reuptake inhibitors.
18  (S allele) results in decreased efficacy of selective serotonin reuptake inhibitors.
19 s and appears to lack drug interactions with selective serotonin reuptake inhibitors.
20 d in mediating the antidepressant actions of selective serotonin reuptake inhibitors.
21                                              Selective serotonin reuptake inhibitors accounted for 80
22 I was significantly lower in patients taking selective serotonin reuptake inhibitors (adjusted hazard
23                      In contrast, the use of selective serotonin reuptake inhibitors (aHR for MOF, 1.
24                  Clinical trial data support selective serotonin reuptake inhibitors and amantadine t
25 summarizes recent developments in the use of selective serotonin reuptake inhibitors and atypical ant
26                 The principal treatments are selective serotonin reuptake inhibitors and behavioural
27 onin transporter (5-HTT) is a key target for selective serotonin reuptake inhibitors and may be invol
28 onflicting evidence and guidelines regarding selective serotonin reuptake inhibitors and suicidality
29            Other tremorogenic drugs, such as selective serotonin reuptake inhibitors and tricyclic an
30 5), benzodiazepines (-0.96, -1.56 to -0.36), selective serotonin-reuptake inhibitors and serotonin-no
31 and pharmacological treatments, particularly selective serotonin-reuptake inhibitors and serotonin-no
32 nin in healthy volunteers with citalopram (a selective serotonin reuptake inhibitor) and contrasted i
33 s fluids, benzodiazapines, and withdrawal of selective serotonin-reuptake inhibitor) and received cyp
34 e transgenerational effects of sertraline, a selective serotonin reuptake inhibitor, and venlafaxine,
35 ective, including tricyclic antidepressants, selective serotonin reuptake inhibitors, and a new agent
36  drugs, including tricyclic antidepressants, selective serotonin reuptake inhibitors, and norepinephr
37 ents, such as atypical antipsychotic agents, selective serotonin reuptake inhibitors, and selective s
38  treatment-related issues: suicide risk with selective serotonin reuptake inhibitors, and the safety
39     We use this line to demonstrate that the selective serotonin reuptake inhibitor antidepressant fl
40  deficits and that the neurogenic effects of selective serotonin reuptake inhibitor antidepressants c
41                      For patients taking non-selective serotonin reuptake inhibitor antidepressants,
42 , but not acute, treatment with tricyclic or selective serotonin reuptake inhibitor antidepressants.
43  of fluoxetine, and thus it remains the only selective serotonin reuptake inhibitor approved by the U
44                                              Selective serotonin reuptake inhibitors are the most wid
45                                              Selective serotonin reuptake inhibitors are widely presc
46                  Current treatments, such as selective serotonin reuptake inhibitors, are not ideal b
47                                Compared with selective serotonin reuptake inhibitors as a drug class,
48 ent evidence continues to support the use of selective serotonin reuptake inhibitors as first-line ph
49 anwhile, evidence supporting the efficacy of selective serotonin reuptake inhibitors, augmentation st
50 a slight shift in prescribing toward the non-selective serotonin reuptake inhibitor bupropion hydroch
51 d risk of ASD associated with treatment with selective serotonin reuptake inhibitors by the mother du
52 ed the 10-year risk of MOF by 36% for use of selective serotonin reuptake inhibitors, by 63% for use
53 -year risk of hip fracture by 57% for use of selective serotonin reuptake inhibitors, by 98% for use
54 ized in a double-blind design to receive the selective serotonin reuptake inhibitor citalopram (20 mg
55            We therefore examined whether the selective serotonin reuptake inhibitor citalopram improv
56                                          The selective serotonin reuptake inhibitor citalopram reduce
57                 A subset of animals received selective serotonin reuptake inhibitor citalopram starti
58                   Open-label trials with the selective serotonin reuptake inhibitor citalopram sugges
59 ogical antagonists (BI-11A7 and BI-2A7); the selective serotonin reuptake inhibitor citalopram was us
60 mobility activity of a subactive dose of the selective serotonin reuptake inhibitor citalopram.
61 ological challenge with an acute dose of the selective serotonin reuptake inhibitor, citalopram, reve
62 e, on the cerebral metabolic response to the selective serotonin reuptake inhibitor, citalopram.
63 seline and in response to challenge with the selective serotonin reuptake inhibitor, citalopram.
64 xamined whether fluoxetine, the prototypical selective serotonin reuptake inhibitor, differentially m
65 her genetic deletion or brief treatment with selective serotonin reuptake inhibitors during developme
66                                       Use of selective serotonin reuptake inhibitors during the secon
67 m effects of exposure to fluoxetine (FLX), a selective serotonin reuptake inhibitor, during adolescen
68         Use of antidepressants, specifically selective serotonin reuptake inhibitors, during the seco
69 rimary target for antidepressants, including selective serotonin reuptake inhibitors (e.g. (S)-citalo
70 f estrogen without its deleterious effect on selective serotonin reuptake inhibitor efficacy.
71 ed during 8 weeks with either placebo or the selective serotonin reuptake inhibitor escitalopram.
72 ssociated with subsequent remission with the selective serotonin reuptake inhibitor escitalopram; thi
73 allele responded significantly better to the selective serotonin reuptake inhibitors escitalopram and
74 tment and 8 weeks after randomization to the selective serotonin reuptake inhibitors escitalopram and
75 tigated whether a 3-week administration of a selective serotonin reuptake inhibitor, expected to incr
76                           Treatment with the selective serotonin reuptake inhibitor fluoxetine suppre
77 ramine, instead mirrored the behavior of the selective serotonin reuptake inhibitor fluoxetine, both
78                 Postnatal treatment with the selective serotonin reuptake inhibitor fluoxetine, evoke
79  were also reversed by administration of the selective serotonin reuptake inhibitor fluoxetine.
80 ety-like behaviors, and is alleviated by the selective serotonin reuptake inhibitor fluoxetine.
81 -HT transport and binding of cocaine and the selective serotonin reuptake inhibitors fluoxetine and e
82  inhibits the antidepressant efficacy of the selective-serotonin reuptake inhibitor fluoxetine (FLX)
83 threo-dihydroxyphenylserine at 5 mg/kg) or a selective serotonin reuptake inhibitor (fluoxetine at 20
84 e individually exposed to acute doses of the selective serotonin reuptake inhibitor, fluoxetine (5 or
85 s with classical therapeutics, including the selective serotonin reuptake inhibitor, fluoxetine.
86 l or progesterone blocked the ability of the selective serotonin reuptake inhibitor, fluvoxamine, to
87 d trials began demonstrating the efficacy of selective serotonin reuptake inhibitors for these condit
88 ial direct-current stimulation (tDCS) with a selective serotonin-reuptake inhibitor for the treatment
89 matized IF-CCKR-2 tg mice with fluoxetine, a selective serotonin reuptake inhibitor, for a period of
90                                Fluoxetine, a selective serotonin reuptake inhibitor, has been found r
91                                Fluoxetine, a selective serotonin reuptake inhibitor, has been reporte
92                          Fluoxetine (FLX), a selective serotonin reuptake inhibitor, has similar effe
93    Although cognitive behavioral therapy and selective serotonin-reuptake inhibitors have shown effic
94  cerebral cortex are powerfully modulated by selective serotonin reuptake inhibitors, however, direct
95 SADHART) tested the safety and efficacy of a selective serotonin reuptake inhibitor in this populatio
96 ajor randomized placebo-controlled trials of selective serotonin reuptake inhibitors in adolescents h
97                                       Use of selective serotonin reuptake inhibitors in depressed pat
98 sk estimates for each drug individually, for selective serotonin reuptake inhibitors in depression tr
99                   The overall risk ratio for selective serotonin reuptake inhibitors in depression tr
100                 Although the acute effect of selective serotonin reuptake inhibitors in elevating syn
101 ts, and could be relevant to some actions of selective serotonin reuptake inhibitors in humans.
102 ctively over a 12-week treatment course with selective serotonin reuptake inhibitors in late-life dep
103  the use of cognitive behavioral therapy and selective serotonin reuptake inhibitors in the treatment
104             Long-term efficacy and safety of selective serotonin reuptake inhibitors in these patient
105           The efficacy and adverse events of selective serotonin reuptake inhibitors in these patient
106 the number of children exposed prenatally to selective serotonin reuptake inhibitors in this populati
107                  We identified citalopram, a selective serotonin reuptake inhibitor, in a small molec
108 take and biological effects of fluoxetine, a selective serotonin reuptake inhibitor, in filter and de
109 profile of using antidepressants, especially selective serotonin reuptake inhibitors, in depressed ch
110  outcomes, but antidepressant treatment with selective serotonin reuptake inhibitors is generally saf
111 pressant paroxetine (Paxil), the most potent selective serotonin reuptake inhibitor known.
112                                              Selective serotonin reuptake inhibitors may provide bene
113                                     Although selective serotonin reuptake inhibitors may reduce morta
114 d MDDs (untreated, n = 12), MDD treated with selective serotonin reuptake inhibitors (MDD*SSRI, n = 6
115 trials of second-generation antidepressants (selective serotonin reuptake inhibitors, nefazodone, ven
116                                       Use of selective serotonin reuptake inhibitors, nonbenzodiazepi
117  with depression classified as responsive to selective serotonin reuptake inhibitors (odds ratio=1.55
118 estigations into the effects of OLZ, but not selective serotonin reuptake inhibitors, on core feature
119 o ongoing antidepressant medication therapy (selective serotonin reuptake inhibitor or serotonin and
120 health and physical health, treatment with a selective serotonin reuptake inhibitor or serotonin-nore
121 nd were randomized to receive either another selective serotonin reuptake inhibitor or venlafaxine, w
122 wed by a 10-week open-label treatment with a selective serotonin reuptake inhibitor or, in some cases
123 xib, ondansetron) either in combination with selective serotonin reuptake inhibitors or as monotherap
124 rol in the treatment of depression by use of selective serotonin reuptake inhibitors or psychological
125 macologically untreated maternal depression, selective serotonin reuptake inhibitors or serotonin and
126 ctively downregulated by the acute action of selective serotonin reuptake inhibitors or serotonin at
127 dence interval [CI] = 1.10-15.14) and use of selective serotonin reuptake inhibitors (OR = 2.66; 95%
128 er, this includes tricyclic antidepressants, selective serotonin reuptake inhibitors, or psychosocial
129                                          The selective serotonin reuptake inhibitor, paroxetine, was
130                       Fluoxetine is the only selective serotonin reuptake inhibitor registered for th
131 cognitive behavioral therapy with or without selective serotonin reuptake inhibitors remains a prefer
132          Whether this model is responsive to selective serotonin reuptake inhibitors remains unspecif
133 ticularly in women with MDD or anxiety, with selective serotonin reuptake inhibitors reported as the
134  effects of classic antidepressants, such as selective serotonin reuptake inhibitors, require a month
135 tion, acute itch triggered by serotonin or a selective serotonin reuptake inhibitor required both HTR
136 r adolescent exposure to fluoxetine (FLX), a selective serotonin reuptake inhibitor, results in chang
137  Only one case report suggested benefit from selective serotonin reuptake inhibitor/serotonin-norepin
138 re may be excess morbidity in critically ill selective serotonin reuptake inhibitor/serotonin-norepin
139                                              Selective serotonin reuptake inhibitor/serotonin-norepin
140 ed for studies of ICU patients with recorded selective serotonin reuptake inhibitor/serotonin-norepin
141 ting, it was generally unclear if outpatient selective serotonin reuptake inhibitor/serotonin-norepin
142 istics in exposed and control groups; use of selective serotonin reuptake inhibitor/serotonin-norepin
143 needed to help clinicians decide when to use selective serotonin reuptake inhibitor/serotonin-norepin
144 8 weeks of antidepressant treatment with the selective serotonin reuptake inhibitor sertraline hydroc
145                                      Chronic selective serotonin reuptake inhibitor (SSRI) administra
146 als have indicated that the combination of a selective serotonin reuptake inhibitor (SSRI) and a stat
147 e disorder, either untreated or treated with selective serotonin reuptake inhibitor (SSRI) antidepres
148 antidepressant medication or specifically to selective serotonin reuptake inhibitor (SSRI) antidepres
149 DA, and displays distinct sensitivity to the selective serotonin reuptake inhibitor (SSRI) antidepres
150 d by 25% following administration of several selective serotonin reuptake inhibitor (SSRI) antidepres
151 cal antipsychotic medications; fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepres
152                       Fluoxetine, one of the selective serotonin reuptake inhibitor (SSRI) antidepres
153                      The association between selective serotonin reuptake inhibitor (SSRI) antidepres
154                  Research has shown that the selective serotonin reuptake inhibitor (SSRI) citalopram
155          This study investigated whether the selective serotonin reuptake inhibitor (SSRI) citalopram
156 ing Caucasian subjects were administered the selective serotonin reuptake inhibitor (SSRI) citalopram
157  lacked the early anxiogenic response to the selective serotonin reuptake inhibitor (SSRI) fluoxetine
158 acy in rats and advantages compared with the selective serotonin reuptake inhibitor (SSRI) fluoxetine
159 depressant (TCA) desipramine (10 mg/kg), the selective serotonin reuptake inhibitor (SSRI) fluoxetine
160 pothesis that 6 weeks' administration of the selective serotonin reuptake inhibitor (SSRI) fluoxetine
161                                          The selective serotonin reuptake inhibitor (SSRI) fluoxetine
162 study revealed that chronic treatment with a selective serotonin reuptake inhibitor (SSRI) impairs th
163            A subset of patients started on a selective serotonin reuptake inhibitor (SSRI) initially
164  an empirically supported psychotherapy with selective serotonin reuptake inhibitor (SSRI) pharmacoth
165 le-blind, randomized controlled trial of the selective serotonin reuptake inhibitor (SSRI) sertraline
166        Prior to beginning treatment with the selective serotonin reuptake inhibitor (SSRI) sertraline
167 e disorder (MDD), but many do not respond to selective serotonin reuptake inhibitor (SSRI) therapy.
168 compounds was synthesized by linking a novel selective serotonin reuptake inhibitor (SSRI) to a PDE4
169                                     Although selective serotonin reuptake inhibitor (SSRI) treatment
170 s examined the relationship between prenatal selective serotonin reuptake inhibitor (SSRI) treatment
171                                              Selective serotonin reuptake inhibitor (SSRI) use during
172 porter (hSERT) were synthesized based on the selective serotonin reuptake inhibitor (SSRI), (S)-cital
173         Effects of duloxetine hydrochloride, selective serotonin reuptake inhibitor (SSRI), and covar
174                                Fluoxetine, a selective serotonin reuptake inhibitor (SSRI), blocks GC
175 postnatal days 8-21) exposure of rats to the selective serotonin reuptake inhibitor (SSRI), citalopra
176            In the presence of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), concentra
177 ors that are not rescued with the prototypic selective serotonin reuptake inhibitor (SSRI), fluoxetin
178  investigated the effects of escitalopram, a selective serotonin reuptake inhibitor (SSRI), on brain
179 -up analyses demonstrated that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), provided
180          Adolescents (ages 12-18 years) with selective serotonin reuptake inhibitor (SSRI)-resistant
181 ic treatment with citalopram, a prototypical selective serotonin reuptake inhibitor (SSRI).
182 ients and after 8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI).
183 esponse to an initial treatment trial with a selective serotonin reuptake inhibitor (SSRI).
184 ients and after ~8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI).
185     Here, we show that when the effects of a selective serotonin reuptake inhibitor (SSRI, citalopram
186                                              Selective serotonin reuptake inhibitors (SSRI's) enhance
187                                              Selective serotonin reuptake inhibitors (SSRI) are aimed
188                                              Selective serotonin reuptake inhibitors (SSRI) are known
189 ve demonstrated that acute administration of selective serotonin reuptake inhibitors (SSRI) can affec
190 ible association between maternal use of the selective serotonin-reuptake inhibitor (SSRI) fluoxetine
191 unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not
192 ar mechanisms explaining hormetic effects of selective serotonin reuptake inhibitors (SSRIs) and 4-no
193 seems to be a correlation between the use of selective serotonin reuptake inhibitors (SSRIs) and a de
194       The strongest evidence supports use of selective serotonin reuptake inhibitors (SSRIs) and cogn
195 olescents in randomized controlled trials to selective serotonin reuptake inhibitors (SSRIs) and cons
196 lasses of antidepressants, prescriptions for selective serotonin reuptake inhibitors (SSRIs) and othe
197 ike behaviors, both of which are reversed by selective serotonin reuptake inhibitors (SSRIs) and the
198                                              Selective serotonin reuptake inhibitors (SSRIs) are a fi
199                                              Selective serotonin reuptake inhibitors (SSRIs) are anti
200                       Compared with placebo, selective serotonin reuptake inhibitors (SSRIs) are asso
201                                              Selective Serotonin Reuptake Inhibitors (SSRIs) are comm
202                                              Selective serotonin reuptake inhibitors (SSRIs) are comm
203                                              Selective serotonin reuptake inhibitors (SSRIs) are comm
204                                              Selective serotonin reuptake inhibitors (SSRIs) are effi
205                                              Selective serotonin reuptake inhibitors (SSRIs) are freq
206                                              Selective serotonin reuptake inhibitors (SSRIs) are ofte
207                                              Selective serotonin reuptake inhibitors (SSRIs) are ofte
208                                              Selective serotonin reuptake inhibitors (SSRIs) are the
209                                              Selective serotonin reuptake inhibitors (SSRIs) are the
210                                              Selective serotonin reuptake inhibitors (SSRIs) are wide
211                                              Selective serotonin reuptake inhibitors (SSRIs) are wide
212                                              Selective serotonin reuptake inhibitors (SSRIs) are wide
213                                              Selective serotonin reuptake inhibitors (SSRIs) are wide
214                                     Although selective serotonin reuptake inhibitors (SSRIs) are wide
215                                          Are selective serotonin reuptake inhibitors (SSRIs) associat
216                                              Selective serotonin reuptake inhibitors (SSRIs) display
217                                       Use of selective serotonin reuptake inhibitors (SSRIs) during p
218 cern about an association between the use of selective serotonin reuptake inhibitors (SSRIs) during p
219            It is unknown whether exposure to selective serotonin reuptake inhibitors (SSRIs) during p
220 e has been ongoing controversy as to whether selective serotonin reuptake inhibitors (SSRIs) exhibit
221  of suicidality in pediatric patients taking selective serotonin reuptake inhibitors (SSRIs) for depr
222  of suicidality in pediatric patients taking selective serotonin reuptake inhibitors (SSRIs) for depr
223 .S. and Dutch data on prescription rates for selective serotonin reuptake inhibitors (SSRIs) from 200
224                                       Use of selective serotonin reuptake inhibitors (SSRIs) has been
225                      Chronic treatments with selective serotonin reuptake inhibitors (SSRIs) have bee
226                        In both rats and men, selective serotonin reuptake inhibitors (SSRIs) impair e
227                   The safety and efficacy of selective serotonin reuptake inhibitors (SSRIs) in adole
228 xamined modulation of synaptic plasticity by selective serotonin reuptake inhibitors (SSRIs) in hippo
229 ies suggested that the treatment response to selective serotonin reuptake inhibitors (SSRIs) in major
230 r (nAChR) blockers potentiate the effects of selective serotonin reuptake inhibitors (SSRIs) in some
231 sion and attention, and the effectiveness of selective serotonin reuptake inhibitors (SSRIs) in treat
232 rs investigated whether in utero exposure to selective serotonin reuptake inhibitors (SSRIs) increase
233       Elevating serotonin (5-HT) levels with selective serotonin reuptake inhibitors (SSRIs) is the m
234                                              Selective serotonin reuptake inhibitors (SSRIs) may incr
235 d, treating animals with MAO-A inhibitors or selective serotonin reuptake inhibitors (SSRIs) normaliz
236  was to assess the effects of treatment with selective serotonin reuptake inhibitors (SSRIs) on the r
237 placebo in meta-analyses of 7 comparisons of selective serotonin reuptake inhibitors (SSRIs) or serot
238 dicines (CSM) advised against treatment with selective serotonin reuptake inhibitors (SSRIs) other th
239                                              Selective serotonin reuptake inhibitors (SSRIs) represen
240                  Compared with pill placebo, selective serotonin reuptake inhibitors (SSRIs) signific
241 ted with PD, and clinical data indicate that selective serotonin reuptake inhibitors (SSRIs) such as
242  and its eutomer, escitalopram (S-(+)-1) are selective serotonin reuptake inhibitors (SSRIs) that are
243 s risk from concomitant use of nsNSAIDs with selective serotonin reuptake inhibitors (SSRIs) was 1.6,
244                                              Selective serotonin reuptake inhibitors (SSRIs) were int
245  recent studies linking in utero exposure to selective serotonin reuptake inhibitors (SSRIs) with per
246 erotonin-norepinephrine reuptake inhibitor), selective serotonin reuptake inhibitors (SSRIs), and mat
247 n between use of antidepressants, especially selective serotonin reuptake inhibitors (SSRIs), and sui
248 ion do not respond to initial treatment with selective serotonin reuptake inhibitors (SSRIs), and thi
249 ear how perinatal exposure to drugs, such as selective serotonin reuptake inhibitors (SSRIs), impacts
250                                              Selective serotonin reuptake inhibitors (SSRIs), in addi
251 rapy were compared for patients who received selective serotonin reuptake inhibitors (SSRIs), new-gen
252  broad range of therapeutic agents including selective serotonin reuptake inhibitors (SSRIs), seroton
253 t of several antidepressant drugs, including selective serotonin reuptake inhibitors (SSRIs), seroton
254  examine the relative efficacy and safety of selective serotonin reuptake inhibitors (SSRIs), seroton
255                                              Selective serotonin reuptake inhibitors (SSRIs), such as
256 lizers, which dampen limbic irritability, or selective serotonin reuptake inhibitors (SSRIs), which m
257 nteraction of fluoxetine and paroxetine, two selective serotonin reuptake inhibitors (SSRIs), with th
258  or Depressive Disorder who are treated with Selective Serotonin Reuptake Inhibitors (SSRIs).
259 red for behavioral and cellular responses to selective serotonin reuptake inhibitors (SSRIs).
260 who had a partial response or no response to selective serotonin reuptake inhibitors (SSRIs).
261 isk of preeclampsia among women treated with selective serotonin reuptake inhibitors (SSRIs).
262 both biochemical and behavioral responses to selective serotonin reuptake inhibitors (SSRIs).
263 during cognitive-behavioral therapy (CBT) or selective serotonin reuptake inhibitors (SSRIs).
264  an important role in modulating response to selective serotonin reuptake inhibitors (SSRIs).
265 tonin in vitro and functionally responded to selective serotonin reuptake inhibitors (SSRIs).
266 been observed in patients chronically taking selective serotonin reuptake inhibitors (SSRIs).
267 ersive behaviour following acute exposure to selective serotonin reuptake inhibitors (SSRIs).
268 roidal anti-inflammatory drugs (NSAIDs), and selective serotonin reuptake inhibitors (SSRIs).
269 iated with the introduction and diffusion of selective serotonin reuptake inhibitors (SSRIs).
270  the population and is commonly treated with selective serotonin reuptake inhibitors (SSRIs; e.g., Pr
271                           Whether the use of selective serotonin-reuptake inhibitors (SSRIs) and othe
272 HMG-CoA) reductase inhibitors (statins), and selective serotonin-reuptake inhibitors (SSRIs) and sero
273                                   The use of selective serotonin-reuptake inhibitors (SSRIs) has been
274 of birth defects after antenatal exposure to selective serotonin-reuptake inhibitors (SSRIs) remains
275  (DR) attenuates the therapeutic activity of selective serotonin-reuptake inhibitors (SSRIs), whereas
276                          Antidepressant use (selective serotonin reuptake inhibitors [SSRIs] or serot
277 ed duloxetine to comparators (venlafaxine or selective serotonin reuptake inhibitors [SSRIs], and ind
278 s, calcium channel blockers, loop diuretics, selective serotonin reuptake inhibitors, statins, and th
279  unintended declines in case finding and non-selective serotonin reuptake inhibitor substitute treatm
280                                              Selective serotonin reuptake inhibitors, such as fluoxet
281 urtailed with subchronic administration of a selective serotonin reuptake inhibitor, suggesting the p
282                      As in major depression, selective serotonin reuptake inhibitors targeting brain
283  participants who required the addition of a selective serotonin reuptake inhibitor to achieve remiss
284                      Sertraline is the first selective serotonin reuptake inhibitor to demonstrate a
285     Behavioral changes were rescued by acute selective serotonin reuptake inhibitor treatment, suppor
286 ses were used to assess cataract surgery and selective serotonin reuptake inhibitor treatment.
287 ve bias develops in patients with MDD during selective serotonin reuptake inhibitor treatment.
288 , anhedonia, and an increased sensitivity to selective serotonin reuptake inhibitor treatment.
289                                  Acute SSRI (selective serotonin reuptake inhibitor) treatment has be
290  nonbenzodiazepine hypnotics, beta-blockers, selective serotonin reuptake inhibitors, tricyclic antid
291 according to whether patients were receiving selective serotonin reuptake inhibitors, tricyclic antid
292 ed to compute odds ratios for differences in selective serotonin reuptake inhibitor use between cases
293                                              Selective serotonin reuptake inhibitor use decreased in
294                                              Selective serotonin reuptake inhibitor use of 1 or more
295                                              Selective serotonin reuptake inhibitor use of 1 or more
296 the potential for pediatric suicidality with selective serotonin reuptake inhibitor use.
297 higher New York Heart Association class, and selective serotonin reuptake inhibitor use.
298 ry cohort of 6024 residents, 1024 (17%) were selective serotonin reuptake inhibitor users compared to
299               For SERT analysis, patients on selective serotonin reuptake inhibitor were excluded (n
300 articipants who were partial responders to a selective serotonin reuptake inhibitor were randomized t

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top